Open AccessPegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
Author(s) -
Abdulraheem Yacoub,
John Mascarenhas,
Heidi E. Kosiorek,
Josef T. Prchal,
Dmitry Berenzon,
Maria R. Baer,
Ellen K. Ritchie,
Richard T. Silver,
Craig M. Kessler,
Elliott F. Winton,
Maria Chiara Finazzi,
Alessandro Rambaldi,
Alessandro M. Vannucchi,
D Leibowitz,
Damiano Rondelli,
Murat O. Arcasoy,
Rosalind Catchatourian,
Joseph Vadakara,
Vittorio Rosti,
Elizabeth O. Hexner,
Marina Kremyanskaya,
Lonette Sandy,
Joseph Tripodi,
Vesjfeld,
Noushin Farnoud,
Elli Papaemmanuil,
Mohamed E. Salama,
Rona Singer-Weinberg,
Raajit K. Rampal,
Judith D. Goldberg,
Tiziano Barbui,
Ruben A. Mesa,
Amylou C. Dueck,
Ronald Hoffman
Publication year - 2019
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood.2019000428
Subject(s) - polycythemia vera , medicine , essential thrombocythemia , anagrelide , alpha interferon , interferon alfa , gastroenterology , immunology , interferon
Yacoub et al report excellent responses to pegylated interferon alfa-2a in patients with hydroxyurea-resistant/intolerant polycythemia vera or essential thrombocythemia.